Intraperitoneal cisplatin in the treatment of refractory or recurrent advanced ovarian carcinoma.
Twenty-three patients with advanced ovarian cancer were entered into a phase II trial of intraperitoneal cisplatin (60 mg/m2 with escalation to 90 mg/m2 per course). All patients had either minimal residual disease after systemic chemotherapy or a recurrence after attainment of a clinically or surgically complete response. After a median follow-up of 3 years, 12 patients had died and of the 11 remaining alive 4 were without recurrence. Survival ranged between 4 and 48+ months with a median of 30 months. A definite survival advantage with this treatment modality does not appear evident and needs to be demonstrated by randomized studies.
ten Tije
B J
BJ
Department of Internal Diseases, St. Clarahospital, Rotterdam, The Netherlands.
Wils
J
J
D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
D002945:Cisplatin